Key regions: United Kingdom, Germany, France, South Korea, Italy
The COVID-19 pandemic has impacted the global healthcare industry, and Rwanda is no exception. As the country continues to battle the virus, the demand for COVID-19 vaccines has increased. In this market analysis, we will explore the trends and developments in the COVID-19 Vaccines market in Rwanda.
Customer preferences: Rwandans have shown a strong interest in getting vaccinated against COVID-19. The government has been actively promoting vaccination campaigns, and many citizens have responded positively. The majority of the population prefers vaccines that have been approved by the World Health Organization (WHO), such as AstraZeneca and Pfizer-BioNTech.
Trends in the market: The COVID-19 vaccine market in Rwanda has seen a surge in demand in recent months. The government has been working to secure vaccine doses from various sources, including the COVAX initiative and bilateral agreements with other countries. As a result, the country has been able to vaccinate a significant portion of its population. However, the market has also faced challenges, such as vaccine hesitancy among some citizens and logistical issues in distributing vaccines to remote areas.
Local special circumstances: Rwanda's healthcare infrastructure has been strengthened in recent years, which has helped the country respond to the pandemic. The government has invested in healthcare facilities and trained healthcare workers to manage COVID-19 cases. Additionally, Rwanda has a history of successful vaccination campaigns, which has helped build public trust in vaccines. However, the country also faces unique challenges, such as a high population density and limited resources in some areas.
Underlying macroeconomic factors: Rwanda's economy has been impacted by the pandemic, with sectors such as tourism and hospitality experiencing significant declines. However, the government has implemented measures to support businesses and stimulate economic growth. The vaccine market has also provided opportunities for local businesses, such as pharmaceutical companies and healthcare providers. Overall, the success of the COVID-19 vaccine market in Rwanda will depend on continued government support, public trust in vaccines, and effective distribution strategies.
Data coverage:
Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.Modeling approach / Market size:
Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.Forecasts:
In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.Additional notes:
Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.
Mon - Fri, 9am - 6pm (EST)
Mon - Fri, 9am - 5pm (SGT)
Mon - Fri, 10:00am - 6:00pm (JST)
Mon - Fri, 9:30am - 5pm (GMT)
Mon - Fri, 9am - 6pm (EST)
